Nephros, Inc. – NASDAQ:NEPH
Nephros stock price today
$4.25
+2.76
+185.23%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Nephros stock price monthly change
-34.93%
month
Nephros stock price quarterly change
-34.93%
quarter
Nephros stock price yearly change
-61.84%
year
Nephros key metrics
Market Cap | 16.23M |
Enterprise value | 12.08M |
P/E | -3.02 |
EV/Sales | 1.20 |
EV/EBITDA | -1.72 |
Price/Sales | 1.45 |
Price/Book | 2.61 |
PEG ratio | 0.03 |
EPS | -0.13 |
Revenue | 14.06M |
EBITDA | -1.27M |
Income | -1.43M |
Revenue Q/Q | -4.73% |
Revenue Y/Y | 21.77% |
Profit margin | -73.54% |
Oper. margin | -51.12% |
Gross margin | 46.39% |
EBIT margin | -51.12% |
EBITDA margin | -9.03% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNephros stock price history
Nephros stock forecast
Nephros financial statements
| Jun 2023 | 3.54M | -433K | -12.21% |
|---|---|---|---|
| Sep 2023 | 3.74M | -182K | -4.86% |
| Dec 2023 | 3.25M | -654K | -20.1% |
| Mar 2024 | 3.52M | -169K | -4.8% |
| 2025 | 18.05M | 538K | 2.98% |
|---|
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 10386000 | 1.73M | 16.67% |
|---|---|---|---|
| Sep 2023 | 10919000 | 2.29M | 21.04% |
| Dec 2023 | 11861000 | 3.50M | 29.53% |
| Mar 2024 | 11416000 | 3.23M | 28.35% |
| Jun 2023 | 226K | 0 | -2K |
|---|---|---|---|
| Sep 2023 | 562K | 0 | -77K |
| Dec 2023 | -237K | -75K | -3K |
| Mar 2024 | -672K | 0 | -2K |
Nephros alternative data
| Aug 2023 | 27 |
|---|---|
| Sep 2023 | 27 |
| Oct 2023 | 27 |
| Nov 2023 | 27 |
| Dec 2023 | 27 |
| Jan 2024 | 27 |
| Feb 2024 | 27 |
| Mar 2024 | 31 |
| Apr 2024 | 31 |
| May 2024 | 31 |
| Jun 2024 | 31 |
| Jul 2024 | 31 |
Nephros other data
6.96%
-72.13%
of NEPH is owned by hedge funds
375.63K
-3.89M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2023 | 2000 | 0 |
| Dec 2023 | 18000 | 0 |
| Mar 2024 | 7000 | 0 |
| May 2024 | 55000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | AMRON ARTHUR H director | Common Stock | 3,000 | $2.25 | $6,735 | ||
Purchase | AMRON ARTHUR H director | Common Stock | 2,000 | $2.22 | $4,442 | ||
Purchase | BANKS ROBERT R. JR. director, officer: President an.. | Common Stock | 50,000 | $2.24 | $112,050 | ||
Purchase | AMRON ARTHUR H director | Common stock | 7,000 | $2.45 | $17,129 | ||
Purchase | BANKS ROBERT R. JR. director, officer: President an.. | Common Stock | 18,000 | $2.2 | $39,654 | ||
Purchase | BANKS ROBERT R. JR. director, officer: President an.. | Common Stock | 1,901 | $1.69 | $3,207 | ||
Purchase | BANKS ROBERT R. JR. director, officer: President an.. | Common Stock | 99 | $1.5 | $149 | ||
Option | ASTOR ANDREW director, officer.. | Warrants (right to buy) | 14,815 | $2.7 | $40,001 | ||
Option | ASTOR ANDREW director, officer.. | Common Stock | 14,815 | $2.7 | $40,001 | ||
Purchase | LOBO WESLEY S. | Common Stock | 1,000 | $7.92 | $7,920 |
| Patent |
|---|
Application Portable System and Process Thereof to Rapidly Detect the Presence, Family of Origin and Ratio of Any Bacteria and Estimate the Endotoxin-Producing Bacteria Levels of a Water Sample Filling date: 15 Jan 2021 Issue date: 15 Jul 2021 |
Application Filling date: 13 Nov 2020 Issue date: 13 May 2021 |
Application Filling date: 21 Apr 2020 Issue date: 29 Oct 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 7 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 10 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
-
What's the price of Nephros stock today?
One share of Nephros stock can currently be purchased for approximately $4.25.
-
When is Nephros's next earnings date?
Unfortunately, Nephros's (NEPH) next earnings date is currently unknown.
-
Does Nephros pay dividends?
No, Nephros does not pay dividends.
-
How much money does Nephros make?
Nephros has a market capitalization of 16.23M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 42.74% to 14.24M US dollars.
-
What is Nephros's stock symbol?
Nephros, Inc. is traded on the NASDAQ under the ticker symbol "NEPH".
-
What is Nephros's primary industry?
Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.
-
How do i buy shares of Nephros?
Shares of Nephros can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Nephros's key executives?
Nephros's management team includes the following people:
- Mr. Andrew Astor Chief Executive Officer, Chief Financial Officer, Pres & Director(age: 68, pay: $309,010)
- Mr. Daron G. Evans Chief Executive Officer of Specialty Renal Products, Inc(age: 51, pay: $300,180)
-
How many employees does Nephros have?
As Jul 2024, Nephros employs 31 workers.
-
When Nephros went public?
Nephros, Inc. is publicly traded company for more then 20 years since IPO on 21 Sep 2004.
-
What is Nephros's official website?
The official website for Nephros is nephros.com.
-
Where are Nephros's headquarters?
Nephros is headquartered at 380 Lackawanna Place, South Orange, NJ.
-
How can i contact Nephros?
Nephros's mailing address is 380 Lackawanna Place, South Orange, NJ and company can be reached via phone at +20 13 435202.
Nephros company profile:
Nephros, Inc.
nephros.comExchange:
NASDAQ
Full time employees:
31
Industry:
Medical - Instruments & Supplies
Sector:
Healthcare
Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
380 Lackawanna Place
South Orange, NJ 07079
South Orange, NJ 07079
CIK: 0001196298
ISIN: US6406714005
CUSIP: 640671400
